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Objectives: A request to report laboratory values to a speciﬁc number of decimal places
represents a delicate balance between clinical interpretation of a true analytical change versus
laboratory understanding of analytical imprecision and signiﬁcant ﬁgures. Prostate speciﬁc
antigen (PSA) was used as an example to determine if an immunoassay routinely reported to the
hundredths decimal place based on signiﬁcant ﬁgure assessment in our laboratory was capable
of providing analytically meaningful results when reported to the thousandths places when
requested by clinicians.
Design and methods: Results of imprecision studies of a representative PSA assay (Roche
MODULAR E170) employing two methods of statistical analysis are reported. Sample pools were
generated with target values of 0.01 and 0.20 μg/L PSA as determined by the E170. Intra-assay
imprecision studies were conducted and the resultant data were analyzed using two independent
statistical methods to evaluate reporting limits.
Results: These statistical methods indicated reporting results to the thousandths place at the
two assessed concentrations was an appropriate reﬂection of the measurement imprecision for
the representative assay. This approach used two independent statistical tests to determine the
ability of an analytical system to support a desired reporting level. Importantly, data were
generated during a routine intra-assay imprecision study, thus this approach does not require
extra data collection by the laboratory.
Conclusions: Independent statistical analysis must be used to determine appropriate signiﬁcant
ﬁgure limitations for clinically relevant analytes. Establishing these limits is the responsibility of
the laboratory and should be determined prior to providing clinical results.
1. Introduction
The discussion of signiﬁcant ﬁgures in result reporting is given relatively little formal attention in the ﬁeld of laboratory
medicine. While a few well-written discussions can be found in the literature [1–3], it is clear that available guidelines or
requirements are not always practiced or well known. Further complicating the topic is the futility of a discussion about signiﬁcant
ﬁgures when laboratory information systems are only capable of reporting in reference to a decimal place. The available literature
provides several useful mechanisms for establishing signiﬁcant ﬁgures for the reporting of a given assay. However, less guidance is
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provided on determining how to establish reporting limits in situations where decimal place consistency is more important than
signiﬁcant ﬁgures. For example, prostate speciﬁc antigen (PSA) may be measured by methods referred to as “ultrasensitive” with
performance claims allowing for the detection of PSA below 0.10 μg/L (0.10 ng/mL). The complication comes from a claimed
sensitivity of 0.010 μg/L; an indication of reporting to the hundredths decimal place, but suggestion of a potentially clinically
meaningful digit in the thousandths decimal place. Further, strict adherence to the two signiﬁcant ﬁgures claim would allow
reporting of 0.011, 0.015 and 0.019 μg/L but not 0.111, 0.115 and 0.119 μg/L. The latter set would require reporting as 0.11, 0.12,
0.12 μg/L causing a perceived loss of resolution between results.
PSA plays a prominent role in the early detection, management, and staging of prostate cancer [4,5].”Ultrasensitive” PSA assays
may be used by some clinicians to detect residual or recurrent disease in patients post-prostatectomy [6,7]. Some manufacturers
oﬀer assays which claim to have a functional sensitivity (coeﬃcient of variation ≤20%) as low as 0.010 μg/L [8–10] or results that
can be reported to two signiﬁcant ﬁgures using the thousandths place. Despite the many advances in the sensitivity and precision of
the PSA assay, laboratories commonly report results in this range to two decimal places since the precision of these assays has not
been well studied at these low concentrations. However, it has been brought to our attention that values reported to the thousands
place are believed by some to aid in patient surveillance.
The goal of this study was to investigate the analytical validity of reporting to the thousandths place regardless of signiﬁcant
ﬁgure protocol for PSA at concentrations typically measured with an “ultrasensitive” method. Here we report the results of
imprecision studies of a PSA assay with a reported functional sensitivity of 0.030 ng/mL (Roche MODULAR E170, Indianapolis, IN)
employing two unique methods of statistical analysis. While straightforward in the approach, the laboratory's assessment of the
precision of high sensitivity assays may have considerable clinical implications.
2. Materials and methods
2.1. Patient samples
Residual serum samples submitted to ARUP Laboratories for PSA testing were de-identiﬁed stored frozen (-20C) for 10–14 days
prior to analysis. This project and its protocols were approved by the University of Utah Institutional Review Board (IRB protocol
#00007275).
2.2. Data collection
Data was obtained by analyzing twenty replicates each of a low value (target 0.01 μg/L) and a high value (target 0.20 μg/L) PSA
sample pool. Selected sample values were chosen to represent clinically relevant PSA concentrations [11,12] and were within the
analytical measurement range of the Roche MODULAR E170 PSA assay 0.014–100 μg/L). After preparation, sample pools were
assayed to obtain an initial value and appropriately adjusted using a high value sample or a low value sample until the desired target
values were obtained.
Aliquots were tested using the Roche MODULAR E170 automated chemistry analyzer. In order to reduce imprecision, all
replicates were performed simultaneously and one measuring cell was inactivated to eliminate any cell-to-cell variation. Testing was
performed according to manufacturer's guidelines and using Roche proprietary reagent for the total PSA assay (Catalog #04491734).
2.3. Statistical methods
Two methods were used to evaluate statistical precision and, thereby, assess the appropriateness of reporting. Method I is
recommended by the National Resources Management and Environment Department [13] that involves using the within-run
variation to direct signiﬁcant ﬁgure reporting. Method II uses a χ2 test to compare performance claim standard deviation (σ) to
observed standard deviation (S). Both of these methods are described in detail below.
2.4. Method I
The Natural Resources Management and Environment Department guideline recommends the following procedure that uses
within-run variation to direct reporting of signiﬁcant ﬁgures and determination of rounding rules (n ≥20):
Calculate the upper boundary bt of the rounding interval a using the standard deviation (s) of the unrounded results, by letting:
bt=s/2. Then choose a equal to the largest decimal unit (e.g., 0.1, 0.01, 0.001 etc.) which does not exceed the calculated bt.
2.5. Method II
The Clinical Laboratory Standards Institute global consensus guideline [14] uses a χ2 test to compare performance claim
standard deviation (σ) to observed standard deviation (s), where s2 is the sample variance, σ2 is the claimed variance, and R is the
total number of determinations or measurements: χ2 =(s2·R) /σ2. The calculated χ2 result is then compared to an upper 95% critical
value for R degrees of freedom and can be treated as a formal hypothesis test of the claimed variance.
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2.6. Data analysis
Data analysis was conducted using Excel (Microsoft Corporation, Bellevue, WA) and the open-source statistical language R (R
Working Group, Vienna, Austria) [15]. Graphs were generated using Adobe Illustrator (Adobe Systems Incorporated, San Jose, CA).
Kolmogorov-Smirnov signiﬁcance testing was performed in R.
3. Results
3.1. Method I: rounding of test results
Table 1 contains the data from twenty replicates of the 0.01 μg/L and 0.20 μg/L PSA sample pools and calculated statistics for
standard deviation (s), upper boundary (bt), and the rounding interval (a). Using this method and these data, the results indicated
acceptability (a < bt) of reporting to the ten thousandths place (0.0001) for the 0.01 μg/L PSA pool and to the thousandths place with
(0.001) for the 0.20 μg/L PSA pool.
3.2. Method II: testing (implied) performance claims
Using a manufacturer claim for precision of 0.001 and an implied standard deviation (σ) of 0.002, we compared the calculated χ2
result to the upper 95% critical value for R degrees of freedom. For our data, R=20 repeated measurements so the 95% cutoﬀ value
for χ2=31.41. Table 1 contains data from twenty replicates of the 0.01 μg/L and the 0.20 μg/L PSA sample pools and the calculated
χ2. Using a 2-sided test, the 0.01 μg/L PSA pool had a statistically signiﬁcantly smaller variance than that which is implied by the
precision, whereas the 0.20 μg/L PSA pool was within speciﬁed tolerance limits. This indicated reporting three decimal places was an
appropriate reﬂection of the precision for both the 0.01 μg/L and the 0.20 μg/L PSA sample pools (Table 1).
3.3. Distribution of raw and rounded results
The distributions of 518 de-identiﬁed patient results using raw values (three decimal places) and rounded values (two decimal
places) are presented in Fig. 1 using ﬁxed bin widths of 0.01 and 0.1 µg/L for values less than 0.1 and 1 μg/L, respectively. A two
sample Kolmogorov-Smirnov test for distribution equality produced a p-value of 0.6869 indicating the overall distributions were not
aﬀected when using raw values or rounded values.
Use of a third decimal place had a potentially signiﬁcant eﬀect for 46 patient results surrounding the 0.01 μg/L concentration
Table 1
Raw PSA data used to determine significant figure reporting limits.
Replicate 0.010 μg/L target value 0.200 μg/L target value
Observed value (μg/L) Observed value (μg/L)
1 0.011 0.198
2 0.012 0.196
3 0.012 0.194
4 0.011 0.200
5 0.012 0.196
6 0.010 0.198
7 0.009 0.198
8 0.011 0.202
9 0.011 0.200
10 0.010 0.201
11 0.011 0.201
12 0.010 0.200
13 0.010 0.199
14 0.012 0.203
15 0.011 0.197
16 0.013 0.201
17 0.012 0.202
18 0.012 0.198
19 0.010 0.200
20 0.012 0.201
s = 0.001020836 s = 0.002336777
Method I bt = 0.0005104178 bt = 0.001168388
a = 0.0001 a = 0.001
Method II χ2= 5.21 χ2= 27.3
s, standard deviation; bt, upper boundary; a, rounding interval.
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associated with an increased probability of biochemical recurrence [12]. Using three decimal places, 23 patient results were <
0.01 μg/L 0.006–0.009 μg/L) while a separate 23 patient results were > 0.01 μg/L 0.011–0.014 μg/L). In contrast, rounding these
results to 2 decimal places resulted in all 46 being reported as 0.01 μg/L.
4. Discussion
New or revised recommendations for treatment or testing may be initiated by physicians pushing the boundaries of what is
known regarding test interpretation. Critical to the success of this paradigm is the general assumption that, in the case of signiﬁcant
ﬁgures and result rounding, the laboratory has identiﬁed the method limitations prior to providing any requested information.
Responsibility in test result reporting rests with the clinical laboratory. In the present study, we describe the ability to accurately
report results to a desired number of decimal places rather than adhering to strict signiﬁcant ﬁgure reporting. We illustrated this
using the PSA assay and veriﬁed reporting to three decimal places when adherence to strict signiﬁcant ﬁgure reporting presents a
challenge. The results of two separate statistical tests indicated that the assay tested was capable of generating results with
statistically acceptable precision to three decimal places. Furthermore, as demonstrated by Fig. 1, the overall distribution of the data
was unchanged with the use of either 2 or 3 decimal places.
It is important to recognize that the conclusions drawn regarding appropriate reporting of decimal places applies only to the PSA
assay described here (Roche E170). Data gathered from other instruments and assays may diﬀer.
Other approaches towards the determination of signiﬁcant digits in the clinical laboratory exist and have been reviewed
previously [2]. The approach presented here uses two independent statistical tests to determine the ability of the analytical system to
support a desired precision target. Importantly, the data used were generated during a routine intra-assay imprecision study and
assessment of reporting would therefore not require any extra data collection by the laboratory. Further, using saved data containing
excess signiﬁcant digits, a laboratory can retrospectively assess precision in the manner described here on demand. Alternatively,
between-run imprecision data could also be assessed.
Although the current report uses PSA as an example, the data presented serves as an important reminder that the laboratory
must fully understand the characteristics of testing methods to ensure integrity of all results.
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